CAPOX Associated With Toxicities of Higher Grade but Improved Disease-Free Survival When Compared With FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer
- 1 September 2014
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 13 (3) , 172-177
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacyAnnals of Oncology, 2011
- Pharmacoeconomic Analysis of Capecitabine versus 5-Fluorouracil/Leucovorin as Adjuvant Therapy for Stage III Colon Cancer in TaiwanValue in Health, 2011
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon CancerJournal of Clinical Oncology, 2011
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC TrialJournal of Clinical Oncology, 2009
- XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysisCurrent Medical Research and Opinion, 2009
- Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukesʼ C Colon CancerClinical Drug Investigation, 2008
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancerThe Lancet, 1995
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1992
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990